TABLE 2.
Circulating ALT, miR‐122 and K18 in individuals with normal ALT (<50 IU/L) in healthy volunteers and first samples taken upon starting ALISTER study or SAEFRIF trial
| Healthy volunteers (n = 28) | Active TB (n = 26) | Latent TB (n = 87) | NTM infection (n = 25) | HIV‐TB coinfection (n = 59) | ||
|---|---|---|---|---|---|---|
| ALT (IU/L) | Median | 18 | 22 | 16 | 16 | 18 |
| [IQR] | [12–22] | [14–27] | [12–23] | [13–25] | [14–27] | |
| Coefficient of variation (%) | 44.0 | 40.7 | 48.4 | 54.3 | 50.3 | |
| MiR‐122 (fM) | Median | 2.88 | 4.14 | 2.92 | 1.57 | ‐ |
| [IQR] | [1.75–3.96] | [1.34–7.56] | [1.46–4.54] | [0.91–3.72] | ||
| Coefficient of variation (%) | 65.8 | 183.4 | 120.6 | 168.5 | ‐ | |
| K18 (U/L) | Median | 210 | 145 | 152 | 163 | 172 |
| [IQR] | [134–259] | [92–220] | [105–215] | [138–263] | [132–276] | |
| Coefficient of variation (%) | 45.9 | 62.2 | 207.8 | 69.2 | 79.4 | |
ALT, alanine transaminase; HIV, human immunodeficiency virus; IQR, interquartile range; MiR, microRNA; NTM, nontuberculous mycobacteria; TB, tuberculosis.